CGP 37849

Suppliers

Names

[ CAS No. ]:
127910-31-0

[ Name ]:
CGP 37849

[Synonym ]:
Proglumide sodium salt
E-2-amino-4-methyl-5-phosphono-3-pentenoic acid
dl-2-amino-4-methyl-5-phosphono-3-*pentenoic acid

Chemical & Physical Properties

[ Density]:
1.506 g/cm3

[ Boiling Point ]:
523.1ºC at 760 mmHg

[ Molecular Formula ]:
C6H12NO5P

[ Molecular Weight ]:
209.13700

[ Flash Point ]:
270.2ºC

[ Exact Mass ]:
209.04500

[ PSA ]:
130.66000

[ LogP ]:
0.22260

MSDS

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Hazard Codes ]:
Xi

[ RIDADR ]:
NONH for all modes of transport

Precursor & DownStream

Precursor

  • CGP 39551
  • E-2-formylamino-4-methyl-5-diethylphosphono-3-pentenoic acid ethyl ester

DownStream

  • CGP 39551

Articles

Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins.

Kidney Int. 63(5) , 1764-75, (2003)

Renal failure has been viewed as a state of cellular calcium toxicity due to the retention of small fast-acting molecules. We have tested this hypothesis and identified potentially neuroexcitatory com...

GSA: behavioral, histological, electrophysiological and neurochemical effects.

Physiol. Behav. 84(2) , 251-64, (2005)

Renal insufficient patients suffer from a variety of complications as direct and indirect consequence of accumulation of retention solutes. Guanidinosuccinic acid (GSA) is an important probable uremic...

Competitive NMDA receptor antagonists and agonists: effects on spontaneous alternation in mice exposed to cerebral oligemia.

Pol. J. Pharmacol. 56(1) , 59-66, (2004)

The purpose of the present study was to investigate the effects of competitive NMDA receptor antagonists,D,L-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (CGP 37849) and its ethyl ester (CGP 3955...


More Articles


Related Compounds

  • CGP 25454A
  • CGP 15425
  • CGP 39551
  • CGP 65015
  • CGP 57698
  • 1-[2-((3-carbamoyl-4-hydroxy)phenoxy)ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]propan-2-ol